Advertisement

Clinical Use of the Calcium-Binding S100B Protein, a Biomarker for Head Injury

  • Ramona Astrand
  • Johan Undén
Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1929)

Abstract

S100B is a calcium-binding protein most abundant in neuronal tissue. It is expressed in glial cells and Schwann cells and exerts both intra- and extracellular effects. Depending on the concentration, secreted S100B exerts either trophic or toxic effects. Its functions have been extensively studied but are still not fully understood. It can be measured in cerebrospinal fluid and in blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders, and malignant melanoma. This chapter provides a short background of protein S100B, commercially available methods of analysis, and its clinical use, especially as a biomarker in minor head injury.

Key words

S100B EF hand Calcium Biomarker Traumatic brain injury Minor head injury Malignant melanoma Neurodegenerative diseases 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739–744CrossRefGoogle Scholar
  2. 2.
    Isobe T, Okuyama T (1981) The amino-acid sequence of the alpha subunit in bovine brain S-100a protein. Eur J Biochem 116:79–86CrossRefGoogle Scholar
  3. 3.
    Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111–1122CrossRefGoogle Scholar
  4. 4.
    Marenholz I, Lovering RC, Heizmann CW (2006) An update of the S100 nomenclature. Biochim Biophys Acta 1763:1282–1283CrossRefGoogle Scholar
  5. 5.
    Kizawa K et al (2011) S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie 93:2038–2047CrossRefGoogle Scholar
  6. 6.
    Ostendorp T et al (2007) Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 26:3868–3878CrossRefGoogle Scholar
  7. 7.
    Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396:201–214CrossRefGoogle Scholar
  8. 8.
    Donato R, Heizmann CW (2010) S100B protein in the nervous system and cardiovascular apparatus in normal and pathological conditions. Cardiovasc Psychiatry Neurol 2010:929712.  https://doi.org/10.1155/2010/929712CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Harpio R, Einarsson R (2004) S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 37:512–518CrossRefGoogle Scholar
  10. 10.
    Haimoto H, Hosoda S, Kato K (1987) Differential distribution of immunoreactive S100-alpha and S100-beta proteins in normal nonnervous human tissues. Lab Investig 57:489–498PubMedGoogle Scholar
  11. 11.
    Wiesmann M et al (1998) Plasma S-100b protein concentration in healthy adults is age- and sex-independent. Clin Chem 44:1056–1058PubMedGoogle Scholar
  12. 12.
    Marchi N et al (2003) Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci 21:109–121PubMedPubMedCentralGoogle Scholar
  13. 13.
    Jonsson H et al (2000) Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 14:698–701CrossRefGoogle Scholar
  14. 14.
    Blomquist S et al (1997) The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth 11:699–703CrossRefGoogle Scholar
  15. 15.
    Raabe A et al (2003) Measurements of serum S-100B protein: effects of storage time and temperature on pre-analytical stability. Clin Chem Lab Med 41:700–703CrossRefGoogle Scholar
  16. 16.
    Hallen M et al (2008) A comparison of two different assays for determining S-100B in serum and urine. Clin Chem Lab Med 46:1025–1029CrossRefGoogle Scholar
  17. 17.
    Raabe A et al (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932CrossRefGoogle Scholar
  18. 18.
    Kunihara T et al (2006) Arterio-jugular differences in serum S-100beta proteins in patients receiving selective cerebral perfusion. Surg Today 36:6–11CrossRefGoogle Scholar
  19. 19.
    Muller K et al (2007) S100B serum level predicts computed tomography findings after minor head injury. J Trauma 62:1452–1456CrossRefGoogle Scholar
  20. 20.
    Astrand R et al (2011) Reference values for venous and capillary S100B in children. Clin Chim Acta 412:2190–2193CrossRefGoogle Scholar
  21. 21.
    Ingebrigtsen T, Romner B, Kock-Jensen C (2000) Scandinavian guidelines for initial management of minimal, mild, and moderate head injuries. The Scandinavian Neurotrauma Committee. J Trauma 48:760–766CrossRefGoogle Scholar
  22. 22.
    af Geijerstam JL, Britton M (2003) Mild head injury - mortality and complication rate: meta-analysis of findings in a systematic literature review. Acta Neurochir 145:843–850 discussion 850CrossRefGoogle Scholar
  23. 23.
    Unden J et al (2005) Serum S100B levels in patients with epidural haematomas. Br J Neurosurg 19:43–45CrossRefGoogle Scholar
  24. 24.
    Unden J, Romner B (2009) A new objective method for CT triage after minor head injury—serum S100B. Scand J Clin Lab Invest 69:13–17CrossRefGoogle Scholar
  25. 25.
    Biberthaler P et al (2001) Elevated serum levels of S-100B reflect the extent of brain injury in alcohol intoxicated patients after mild head trauma. Shock 16:97–101CrossRefGoogle Scholar
  26. 26.
    Biberthaler P et al (2001) Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma. World J Surg 25:93–97CrossRefGoogle Scholar
  27. 27.
    Ingebrigtsen T et al (2000) The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj 14:1047–1055CrossRefGoogle Scholar
  28. 28.
    Mussack T et al (2002) Immediate S-100B and neuron-specific enolase plasma measurements for rapid evaluation of primary brain damage in alcohol-intoxicated, minor head-injured patients. Shock 18:395–400CrossRefGoogle Scholar
  29. 29.
    Poli-de-Figueiredo LF et al (2006) Measurement of S-100B for risk classification of victims sustaining minor head injury—first pilot study in Brazil. Clinics (Sao Paulo) 61:41–46CrossRefGoogle Scholar
  30. 30.
    Unden J, Romner B (2010) Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 25:228–240CrossRefGoogle Scholar
  31. 31.
    Kleine TO, Benes L, Zofel P (2003) Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull 61:265–279CrossRefGoogle Scholar
  32. 32.
    Unden J et al (2005) Raised serum S100B levels after acute bone fractures without cerebral injury. J Trauma 58:59–61CrossRefGoogle Scholar
  33. 33.
    Anderson RE et al (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48:1255–1258 discussion 1258–1260PubMedGoogle Scholar
  34. 34.
    Biberthaler P et al (2000) Influence of alcohol exposure on S-100b serum levels. Acta Neurochir Suppl 76:177–179PubMedGoogle Scholar
  35. 35.
    Biberthaler P et al (2006) Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 25:446–453CrossRefGoogle Scholar
  36. 36.
    Zongo D et al (2011) S100-B protein as a screening tool for the early assessment of minor head injury. Ann Emerg Med 59:209–218CrossRefGoogle Scholar
  37. 37.
    Unden J et al (2013) Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med 14:33.  https://doi.org/10.1186/1741-7015-11-50CrossRefGoogle Scholar
  38. 38.
    Calcagnile O, Anell A, Unden J (2016) The addition of S100B to guidelines for management of mild head injury is potentially cost saving. BMC Neurol 16:200.  https://doi.org/10.1186/s12883-016-0723-zCrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Unden L et al (2015) Validation of the Scandinavian guidelines for initial management of minimal, mild and moderate traumatic brain injury in adults. BMC Med 13:292.  https://doi.org/10.1186/s12916-015-0533-yCrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Raabe A, Grolms C, Seifert V (1999) Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg 13:56–59CrossRefGoogle Scholar
  41. 41.
    Nylen K et al (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91CrossRefGoogle Scholar
  42. 42.
    da Rocha AB et al (2006) Role of serum S100B as a predictive marker of fatal outcome following isolated severe head injury or multitrauma in males. Clin Chem Lab Med 44:1234–1242CrossRefGoogle Scholar
  43. 43.
    Wiesmann M et al (2010) Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 121:178–185CrossRefGoogle Scholar
  44. 44.
    Vos PE et al (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793CrossRefGoogle Scholar
  45. 45.
    Raabe A et al (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483CrossRefGoogle Scholar
  46. 46.
    Woertgen C et al (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130CrossRefGoogle Scholar
  47. 47.
    Nylen K et al (2008) Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir 150:221–227 discussion 227CrossRefGoogle Scholar
  48. 48.
    Bohmer AE et al (2011) Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 68:1624–1631CrossRefGoogle Scholar
  49. 49.
    Dimopoulou I et al (2003) Protein S-100b serum levels in trauma-induced brain death. Neurology 60:947–951CrossRefGoogle Scholar
  50. 50.
    Rodriguez-Rodriguez A et al (2016) S100B and neuron-specific enolase as mortality predictors in patients with severe traumatic brain injury. Neurol Res 38:130–137CrossRefGoogle Scholar
  51. 51.
    Raabe A et al (2004) S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients. Neurol Res 26:440–445CrossRefGoogle Scholar
  52. 52.
    Unden J et al (2007) Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99CrossRefGoogle Scholar
  53. 53.
    Thelin EP, Nelson DW, Bellander BM (2014) Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury. Neurocrit Care 20:217–229CrossRefGoogle Scholar
  54. 54.
    Bellander BM et al (2011) Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B. Acta Neurochir 153:90–100CrossRefGoogle Scholar
  55. 55.
    Olivecrona M et al (2009) S-100B and neuron specific enolase are poor outcome predictors in severe traumatic brain injury treated by an intracranial pressure targeted therapy. J Neurol Neurosurg Psychiatry 80:1241–1247CrossRefGoogle Scholar
  56. 56.
    Pelinka LE et al (2003) Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 19:195–200CrossRefGoogle Scholar
  57. 57.
    Bechtel K et al (2009) Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics 124:e697–e704CrossRefGoogle Scholar
  58. 58.
    Mondello S et al (2016) Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury. Sci Rep 6:28203. https://doi.org/10.1038/srep28203Google Scholar
  59. 59.
    Papa L et al (2015) In children and youth with mild and moderate traumatic brain injury GFAP out-performs S100beta in detecting traumatic intracranial lesions on CT. J Neurotrauma 33:58–64CrossRefGoogle Scholar
  60. 60.
    Berger RP et al (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 103:61–68PubMedGoogle Scholar
  61. 61.
    Castellani C et al (2009) Neuroprotein s-100B—a useful parameter in paediatric patients with mild traumatic brain injury? Acta Paediatr 98:1607–1612CrossRefGoogle Scholar
  62. 62.
    Castellani C et al (2008) Reference ranges for neuroprotein S-100B: from infants to adolescents. Clin Chem Lab Med 46:1296–1299CrossRefGoogle Scholar
  63. 63.
    Simon-Pimmel J et al (2017) Reference ranges for serum S100B neuroprotein specific to infants under four months of age. Clin Biochem 50:1056–1060CrossRefGoogle Scholar
  64. 64.
    Oris C et al (2018) The biomarker S100B and mild traumatic brain injury: a meta-analysis. Pediatrics 141.  https://doi.org/10.1542/peds.2018-0037CrossRefGoogle Scholar
  65. 65.
    Petzold A et al (2003) Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease. Neurosci Lett 336:167–170CrossRefGoogle Scholar
  66. 66.
    Rothermundt M et al (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614–632CrossRefGoogle Scholar
  67. 67.
    Schroeter ML et al (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia—original research and meta-analysis. Psychiatry Res 167:66–72CrossRefGoogle Scholar
  68. 68.
    Beer C et al (2010) Systemic markers of inflammation are independently associated with S100B concentration: results of an observational study in subjects with acute ischaemic stroke. J Neuroinflammation 7:71.  https://doi.org/10.1186/1742-2094-7-71CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Peskind ER et al (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease. Neurochem Int 39:409–413CrossRefGoogle Scholar
  70. 70.
    Chaves ML et al (2010) Serum levels of S100B and NSE proteins in Alzheimer’s disease patients. J Neuroinflammation 7:6.  https://doi.org/10.1186/1742-2094-7-6CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Gruden MA et al (2007) Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 186:181–192CrossRefGoogle Scholar
  72. 72.
    Mitosek-Szewczyk K et al (2011) Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse. Folia Neuropathol 49:191–196PubMedGoogle Scholar
  73. 73.
    Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: an update. Gen Physiol Biophys 28 Spec No Focus:F76–F81PubMedGoogle Scholar
  74. 74.
    Yelmo-Cruz S, Morera-Fumero AL, Abreu-Gonzalez P (2013) S100B and schizophrenia. Psychiatry Clin Neurosci 67:67–75CrossRefGoogle Scholar
  75. 75.
    Hauschild A et al (1999) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338–344CrossRefGoogle Scholar
  76. 76.
    Weide B et al (2012) Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer 107:422–428CrossRefGoogle Scholar
  77. 77.
    Hauschild A et al (1999) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9:155–161CrossRefGoogle Scholar
  78. 78.
    Hartman KG et al (2013) The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med Chem 5:97–109CrossRefGoogle Scholar
  79. 79.
    Molina R et al (2002) S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 23:39–44CrossRefGoogle Scholar
  80. 80.
    Muller K et al (2006) Analysis of protein S-100B in serum: a methodological study. Clin Chem Lab Med 44:1111–1114CrossRefGoogle Scholar
  81. 81.
    Alber B et al (2005) Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma. Clin Chem Lab Med 43:557–563CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ramona Astrand
    • 1
  • Johan Undén
    • 2
  1. 1.Department of NeurosurgeryRigshospitalet, Copenhagen University HospitalCopenhagenDenmark
  2. 2.Department of Anaesthesia and Intensive CareLänssjukhuset HallandHalmstadSweden

Personalised recommendations

Cite protocol

Buy options